60 Results for "

VEGFR2/KDR

" in MedChemExpress (MCE) Product Catalog:
Products (60)

60 Results for "VEGFR2/KDR" in MCE Product Catalog:

  • Targets Recommended:
28
28 Publications Verification
Cat. No.: HY-10260
CAS No.: 443913-73-3
Purity:  99.95%
Synonyms: ZD6474
Vandetanib (D6474) is a potent, orally active, and blood-brain-barrier penetrate inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-10203
CAS No.: 212141-54-3
Purity:  99.93%
Synonyms: PTK787; ZK-222584; CGP-79787
Target:  

VEGFR

Research Areas:  

Cancer

Vatalanib (PTK787; ZK-222584; CGP-79787) is an inhibitor of VEGFR2/KDR with IC50 of 37 nM.
loading...
    loading...
15
15 Cited Publications
Cat. No.: HY-12018
CAS No.: 212141-51-0
Purity:  99.68%
Synonyms: PTK787 dihydrochloride; ZK-222584 dihydrochloride; CGP-797870 dihydrochloride
Vatalanib dihydrochloride (PTK787 dihydrochloride) is a BBB-permeable VEGFR2/KDR inhibitor with an IC50 of 37 nM.
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-112306
CAS No.: 1442472-39-0
Purity:  98.21%
Synonyms: DCC-2618
Research Areas:  

Cancer

Ripretinib (DCC-2618) is an orally bioavailable, selective KIT and PDGFRA switch-control inhibitor. Ripretinib (DCC-2618) targets and binds to both wild-type and mutant forms of KIT and PDGFRA specifically at their switch pocket binding sites, thereby preventing the switch from inactive to active conformations of these kinases and inactivating their wild-type and mutant forms. Ripretinib (DCC-2618) also inhibits multiple other kinase targets, such as FLT3 and KDR (or VEGFR-2) . DCC-2618 exerts antineoplastic effect and induces apoptosis .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10987A
CAS No.: 934353-76-1
Purity:  99.99%
Research Areas:  

Cancer

ENMD-2076 is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10987
CAS No.: 1453868-32-0
Purity:  99.41%
Research Areas:  

Cancer

ENMD-2076 Tartrate is a multi-targeted kinase inhibitor with IC50s of 1.86, 14, 58.2, 15.9, 92.7, 70.8, 56.4 nM for Aurora A, Flt3, KDR/VEGFR2, Flt4/VEGFR3, FGFR1, FGFR2, Src, PDGFRα, respectively.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-P81643
Synonyms: KDR; FLK1; VEGFR2; Vascular endothelial growth factor receptor 2; VEGFR-2; Fetal liver kinase 1; FLK-1; Kinase insert domain receptor; KDR; Protein-tyrosine kinase receptor flk-1; CD antigen CD309

Host:  

Rabbit

Application:  

WB, IHC-P, IHC-F, ICC/IF, ELISA

Reactivity:  

Human, Mouse

loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P1663
CAS No.: 272121-15-0
Target:  

VEGFR

Research Areas:  

Others

ATWLPPR Peptide is a biological active peptide. (This peptide is a specific VEGFR2/KDR heptapeptide antagonist, it binds VEGFR2 (KDR/flk), completely inhibiting VEGF binding to KDR and preventing VEGF-induced angiogenesis in-vivo. It specifically inhibits human endothelial cell proliferation in-vitro and totally abolishes VEGF-induced angiogenesis in-vivo.)
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P70552
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: KDR; Fetal Liver Kinase 1; Kinase Insert Domain Receptor; Vascular Endothelial Growth Factor Receptor 2 Variant; Vascular Endothelial Growth Factor Receptor 2; Tyrosine Kinase Growth Factor Receptor; VEGFR2; Receptor Protein-Tyrosine Kinase; FLK1; Fetal L
Species:  
Human
Source:  
HEK293
loading...
    loading...
Cat. No.: HY-P99768
CAS No.: 2095504-49-5
Synonyms: TTAC-0001; Tanibirumab

Target:  

VEGFR

Research Areas:  

Cancer

Olinvacimab (TTAC-0001) is a fully human anti-VEGFR2 monoclonal antibody. Olinvacimab inhibits VEGF binds to KDR with a Kd value of 0.23 nM. Olinvacimab has antiangiogenic activity. Olinvacimab can be used for the research of recurrent glioblastoma and breast cancer .
loading...
    loading...
Cat. No.: HY-P5438
Research Areas:  

Others

Srctide is a biological active peptide. (This is a peptide substrate for many protein kinases, such as Blk, BTK, cKit, EPHA1, EPHB2, EPHB3, ERBB4, FAK, Flt3, IGF-1R, ITK, Lck, MET, MUSK, Ret, Src, TIE2, TrkB, VEGF-R1 (Flt-1) and VEGF-R2 (KDR).)
loading...
    loading...
Cat. No.: HY-119757
CAS No.: 168835-90-3
Purity:  99.08%
Synonyms: SU1433; AG1433
Target:  

PDGFR VEGFR

Research Areas:  

Cancer

Tyrphostin AG1433 (SU1433) is a tyrosine kinases inhibitor. AG1433 is also a selective PDGFRβ and VEGFR-2 (Flk-1/KDR) inhibitor with IC50s of 5.0 μM and 9.3 μM, respectively. Tyrphostin AG1433 prevents blood vessel formation .
loading...
    loading...
Cat. No.: HY-146369
CAS No.: 2353417-85-1
Target:  

PROTACs VEGFR

Research Areas:  

Cancer

PROTAC VEGFR-2 degrader-2 is a VEGFR-2 (KDR) PROTAC degrader with weak inhibitory activity against VEGFR-2 (IC50 > 1 μM). It is applicable to the research of cancer-related pathological angiogenesis .
loading...
    loading...
Cat. No.: HY-10260B
CAS No.: 524722-52-9
Synonyms: ZD6474 hydrochloride
Target:  

VEGFR Autophagy Apoptosis

Research Areas:  

Cancer

Vandetanib hydrochloride (D6474 hydrochloride) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib hydrochloride also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
loading...
    loading...
Cat. No.: HY-101628
CAS No.: 408502-06-7
Synonyms: KDR-in-4
Target:  

VEGFR

Research Areas:  

Cardiovascular Disease

VEGFR-2-IN-9 (KDR-in-4) is a potent kinase insert domain-containing receptor (KDR/VEGFR2) inhibitor with an IC50 of 7 nM.
loading...
    loading...
Cat. No.: HY-P990543

Target:  

VEGFR

Research Areas:  

Inflammation/Immunology

The Anti-VEGFR2/KDR/CD309 Antibody (AT001) is a humanized antibody expressed in CHO cells that targets VEGFR2/KDR/CD309. The Anti-VEGFR2/KDR/CD309 Antibody (AT001) contains a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for the Anti-VEGFR2/KDR/CD309 Antibody (AT001) can be referenced as Human IgG4 kappa, Isotype Control (HY-P99003).
loading...
    loading...
Cat. No.: HY-125741
CAS No.: 501693-25-0
Purity:  98.66%
Target:  

Tie VEGFR

Research Areas:  

Cancer

GW768505A free base is a potent dual inhibitor of VEGFR2 (KDR) and Tie-2, with a pIC50 of 7.81 for VEGFR2. GW768505A free base has anti-angiogenic activity .
loading...
    loading...
Cat. No.: HY-10260R
CAS No.: 443913-73-3
Synonyms: ZD6474 (Standard)
Research Areas:  

Cancer

Vandetanib (Standard) is the analytical standard of Vandetanib. This product is intended for research and analytical applications. Vandetanib (D6474) is a potent, orally active inhibitor of VEGFR2/KDR tyrosine kinase activity (IC50=40 nM). Vandetanib also has activity versus the tyrosine kinase activity of VEGFR3/FLT4 (IC50=110 nM) and EGFR/HER1 (IC50=500 nM) .
loading...
    loading...
Cat. No.: HY-123586
CAS No.: 791807-02-8
Target:  

MEK VEGFR FLT3 PDGFR

Research Areas:  

Cancer

L-783277 (Compound 4) is a MEK inhibitor (IC50 = 4 nM). L-783277 has potent inhibitory activity against a variety of kinases, including VEGFR2/3, FLT1/3/4, MEK1/2, KDR, and PDGFRα, but has low selectivity for the kinase community. L-783277 inhibits viability (IC50 = 22 mM) and cell proliferation (IC50 = 21 mM) of H295R cells. L-783277 could be used in research on cancers such as adrenocortical carcinoma .
loading...
    loading...
Cat. No.: HY-168114
CAS No.: 2648279-76-7
Target:  

FLT3 PDGFR VEGFR

Research Areas:  

Cancer

Multi-kinase inhibitor 3 (compound 12) is a potent and orally active multikinase inhibitor with IC50 values of 1.59, 1.23, 1.19, 0.59, 0.22, 1.15 nM for FLT1/VEGFR1, KDR/VEGFR2, FLT4/VEGFR3, FLT3, PDGFRα, PDGFRβ, respectively. Multi-kinase inhibitor 3 shows antiproliferative activity. Multi-kinase inhibitor 3 shows anticancer activity .
loading...
    loading...